J. Papacharalambous

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

S. Chimenti, H. Valdez, F. Valenzuela, 2015, The Lancet.

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis

E. Peeva, M. Gooderham, S. Forman, 2019, JAMA dermatology.

Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With Abrocitinib

J. Silverberg, V. Sikirica, J. Cappelleri, 2021, Dermatitis : contact, atopic, occupational, drug.

TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-blind, Placebo-controlled Trial.

E. Peeva, S. Forman, Y. Poulin, 2020, The Journal of investigative dermatology.

Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient‐reported outcomes from a Phase 3 study

H. Valdez, C. Paul, F. Valenzuela, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial

M. Gooderham, K. Papp, R. Bissonnette, 2016, The British journal of dermatology.

Chemical Peels and Microdermabrasion in Skin of Color

Tanasha Sylvester, F. Cook-Bolden, J. Papacharalambous, 2013 .

Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD

M. Lebwohl, J. Cappelleri, E. Peeva, 2020, Dermatology and Therapy.